The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...
Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.
Eli Lilly’s Zepbound is still viewed as the leading weight-loss shot, according to a ...
Pfizer made one thing clear this week: It's officially back in the obesity race.